Research Overview
Where Crystagen sits in the bioregulator family
The Khavinson programme began with tissue-derived polypeptide complexes — Thymalin from thymus, Epithalamin from pineal — and moved toward defined synthetic short peptides said to carry the same activity. Crystagen is the immune-associated member of that synthetic set. Its close neighbours make a useful comparison series: Vilon (Lys-Glu) is a basic-acidic dipeptide assigned to the same tissue, while the AEDx tetrapeptides differ only in their terminal residue. Studies that vary one residue at a time across this set are the most informative way to test whether the claimed tissue specificity is real.
The proposed mechanism
- Direct interaction of short charged peptides with DNA, particularly at specific promoter sequences
- Reported binding to histones and other chromatin-associated proteins, with consequent effects on transcriptional accessibility
- Downstream changes in gene and protein expression measured in lymphocyte and tissue-culture models
- Effects on cell proliferation and differentiation markers in ageing rodent models
The physical plausibility of a tripeptide achieving sequence-selective DNA recognition is debated, and it is the central point on which independent evaluation of this literature turns.
What the published work covers
Practical experimental notes
Very short peptides present analytical challenges: weak chromophores make UV detection insensitive, so mass spectrometry is preferred for identity and quantification. The two acidic side chains give the molecule strong anionic character at physiological pH, which affects ion-exchange behaviour and can cause adsorption losses on certain surfaces. Serum peptidase stability is also short, so incubation times in cell work should be reported explicitly.
